Edmond DE Rothschild Holding S.A. Invests $2.18 Million in Nurix Therapeutics, Inc. $NRIX

Key Points

• Edmond DE Rothschild Holding bought 90,000 Nurix Therapeutics shares worth approximately $2.18 million, giving it a 0.09% stake. Several other institutional investors also recently initiated or increased positions.
• Analyst sentiment remains broadly positive: 13 analysts rate NRIX a Buy, with one Hold and one Sell, producing a “Moderate Buy” consensus and an average price target of $34.21.
• Nurix reported a quarterly loss of $0.81 per share, below the $0.73 consensus estimate, while revenue of $9.04 million missed expectations of $15.29 million. Shares opened at $27.05, near their 52-week high of $28.23.

Edmond DE Rothschild Holding S.A. purchased a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 90,000 shares of the company's stock, valued at approximately $2,183,000. Edmond DE Rothschild Holding S.A. owned 0.09% of Nurix Therapeutics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of NRIX. Larson Financial Group LLC raised its position in Nurix Therapeutics by 339.0% during the 4th quarter. Larson Financial Group LLC now owns 1,541 shares of the company's stock worth $29,000 after buying an additional 1,190 shares during the last quarter. Intesa Sanpaolo Wealth Management acquired a new stake in shares of Nurix Therapeutics in the 4th quarter worth $31,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Nurix Therapeutics in the fourth quarter valued at about $33,000. KBC Group NV purchased a new stake in shares of Nurix Therapeutics in the first quarter valued at about $34,000. Finally, Wexford Capital LP acquired a new position in shares of Nurix Therapeutics during the third quarter worth about $41,000.

Insider Buying and Selling

In other Nurix Therapeutics news, CFO Houte Hans Van sold 4,761 shares of the business's stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $24.36, for a total transaction of $115,977.96. Following the sale, the chief financial officer directly owned 40,166 shares in the company, valued at approximately $978,443.76. The trade was a 10.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 4,356 shares of the business's stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $25.00, for a total transaction of $108,900.00. Following the completion of the sale, the insider owned 117,227 shares in the company, valued at $2,930,675. This represents a 3.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 25,314 shares of company stock worth $589,361. Insiders own 6.70% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Needham & Company LLC reissued a "buy" rating and set a $34.00 price target on shares of Nurix Therapeutics in a report on Tuesday, August 4th. Stifel Nicolaus boosted their target price on Nurix Therapeutics from $34.00 to $40.00 and gave the stock a "buy" rating in a research report on Friday, July 10th. Mizuho increased their target price on Nurix Therapeutics from $30.00 to $34.00 and gave the stock an "outperform" rating in a research note on Monday, July 13th. Weiss Ratings reissued a "sell (d-)" rating on shares of Nurix Therapeutics in a research note on Friday, July 17th. Finally, Jefferies Financial Group raised their price target on Nurix Therapeutics from $41.00 to $45.00 and gave the company a "buy" rating in a report on Monday, June 8th. Thirteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $34.21.

Nurix Therapeutics Stock Down 2.7%

Shares of NRIX opened at $27.05 on Friday. Nurix Therapeutics, Inc. has a 52-week low of $8.19 and a 52-week high of $28.23. The company has a 50-day simple moving average of $23.24 and a 200-day simple moving average of $18.59. The company has a market capitalization of $2.81 billion, a PE ratio of -7.84 and a beta of 1.79.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its quarterly earnings data on Thursday, July 9th. The company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.73) by ($0.08). Nurix Therapeutics had a negative return on equity of 76.09% and a negative net margin of 928.44%.The company had revenue of $9.04 million for the quarter, compared to analysts' expectations of $15.29 million. On average, research analysts anticipate that Nurix Therapeutics, Inc. will post -2.73 EPS for the current year.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company's pipeline includes multiple programs in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source